Sorafenib in Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation

Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to urology practice. The drugs used for management are used in a very limited number of patients and only for clear cell histology. We present a case where we administered sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, to a patient with metastatic renal cell carcinoma of clear cell histology. We found that our results were different from those of previously reported studies, because sarcomatoid differentiation was evident in a histological examination of this case. There was an excellent response to sorafenib. This case report might provide evidence that antiangiogenic agents may be active in any histological type of renal cell carcinoma. However, there are no available data to demonstrate the duration of response and survival benefit

The comparison of urodynamic findings in women with various types of urinary incontinence

WOS: 000337913500015PubMed ID: 24856491Purpose: We aimed to determine the differences of the urodynamic findings of mix urinary incontinence (MUI), urge urinary incontinence (UUI), and stress urinary incontinence (SUI), and to evaluate the urodynamic findings in different groups by using bladder sensitivity index (BSI). Materials and Methods: The data of 99 patients who underwent urodynamic testing related to the suspicion of SUI, UUI or MUI were analysed. This analysis included a retrospective evaluation of patients' cards, voiding diaries, and urodynamic reports. At filling cystometry, the parameters of first sensation of bladder filling (FSBF), first desire to void (FDV), strong desire to void (SDV), and bladder capacity (V-max)(,) which were related to the bladder sensation, were determined. Subsequently, uroflowmetric findings were recorded during bladder emptying. BSI was defined as the ratio of V-max/FDV. These results were statistically compared among the goups. Results: The sample included 35(35.5%) MUI, 33(33.3%) UUI and 31 (31.1%) SUI. The mean ages were similar in all groups (P = 0.868). The mean FSBF, FDV, SDV and Vmax values were significantly different among groups (p = 0.004, p < 0.001, p < 0.001, p < 0.001 respectively). Nevertheless, there was no statistically significant difference among the mean daily voiding accounts (P = 0.005). Although the mean maximum flow rate (Q(max)) values were similar (P = 0.428), the mean maximum detrusor pressure (Pdet(max)) values were significantly different (P = 0.021). The mean BSI values showed no significant differences (P = 0.097). Conclusions: It was concluded that while the use of urodynamic testing could contribute to the management of urinary incontinence, the indexes including BSI requere more detailed and comprehensive studies

Adipocytokine levels in benign prostate hyperplasia and prostate cancer patients

The occurrence of prostate cancer in men is one of the most common types of cancer. Recent studies have found important links between cancer and adipocytokines. Adipocytokines are thought to be factors in the occurrence of a variety of diseases. In addition, adipocytokines studies in cancer patients have shown that these hormones may have an effect in the formation of cancer. The objective of this study was to evaluate the relationship between adiponectin, resistin, and leptin levels in BHP and prostate cancer patients. The study was conducted between September 2012 and April 2013 at the Department of Medical Biochemistry and the Department of Urology. Blood samples were collected from 20 people in the same age range who had been diagnosed by examination and biopsy as having BHP (benign prostatic patients) and prostate cancer patients who had not been operated on. Leptin, adiponectin, resistin, and human serum levels were measured using ELISA kit. In the prostate cancer group, serum adiponectin and resistin levels were significantly lower than in the BHP group. However, serum leptin levels in the prostate cancer group were not significantly different from those in the BHP group. This information and our own findings show that adiponectin and resistin, which are from the adipocytokine family, may play an important role in the progression of prostate cancer, and thus it may be possible to use them as diagnostic markers. Therefore, similar studies should be considered with a greater number of patients at different stages. [Med-Science 2017; 6(3.000): 418-23

The long-term results of temporary urethral stent placement for the treatment of recurrent bulbar urethral stricture disease

ABSTRACT Aim: To evaluate the long term outcomes of temporary urethral stent placement for the treatment of recurrent bulbar urethral stricture. Materials and Methods: Twenty-eight patients who underwent temporary polymer coated urethral stent placement due to recurrent bulbar urethral stricture between 2010 and 2014 were enrolled in the study. The long term outcomes of the patients were analyzed. Results: The mean age of the patients was 62.3±6.4 (44&#8211;81). The overall clinical success was achieved in 18 (64.2%) of the 28 patients at a median (range) follow-up of 29 (7&#8211;46) months. No patient reported discomfort at the stent site. Stone formation was observed at the urethral stent implantation area only in one patient. Stenosis occurred in the distal end of the stents in two patients and took place in bulbar urethra in seven patients after removed the stents. The mean maximum urine flow rates were 6.24±2.81mL/sec and 19.12±4.31mL/sec before and at 3 months after the procedure, respectively. Conclusion: In this study, the success rate of temporary urethral stent placement has remained at 64.2% at a median follow-up of 29 months. Therefore, our outcomes have not achieved desired success rate for the standard treatment of recurrent bulbar urethral stricture